Table 2.
Outcomes, incidence rates, and effect estimates for primary analysis.
| Medicaid | Optum | |||||
|---|---|---|---|---|---|---|
| Outcomes during follow-up | N | |||||
| SCA/VA | 714 | 385 | ||||
| SCD/fatal VA | 375 | — | ||||
| Measure of outcome occurrence | Crude incidence rate, per 1,000 person-years (95% confidence interval) | |||||
| SCA/VA | 3.55 (3.29–3.82) | 1.95 (1.76–2.15) | ||||
| SCD/fatal VA | 1.86 (1.68–2.06) | — | ||||
| Relative effect estimates for outcome | Hazard Ratio (95% confidence interval) | |||||
| Glipizide | Glimepiride | Glyburide | Glipizide | Glimepiride | Glyburide | |
| SCA/VA | ||||||
| Unadjusted* | 1.00 (reference) | 0.96 (0.79–1.16) | 0.78 (0.66–0.93) | 1.00 (reference) | 0.75 (0.59–0.96) | 0.94 (0.74–1.20) |
| hdPS-adjusted** | 1.00 (reference) | 1.17 (0.96–1.42) | 0.87 (0.74–1.03) | 1.00 (reference) | 0.84 (0.65–1.08) | 1.11 (0.86–1.42) |
| SCD/fatal VA | ||||||
| Unadjusted† | 1.00 (reference) | 1.03 (0.79–1.34) | 0.83 (0.66–1.05) | — | — | — |
| hdPS-adjusted‡ | 1.00 (reference) | 1.33 (1.02–1.75) | 0.91 (0.72–1.20) | — | — | — |
hdPS = high-dimensional propensity score; SCA = sudden cardiac arrest; SCD = sudden cardiac death; VA = ventricular arrhythmia.
*Failed a test for non-proportional hazards in Medicaid (p = 0.034), but not in Optum (p = 0.566).
**Did not fail a test for non-proportional hazards in Medicaid (p = 0.052) or Optum (p = 0.658).
†Did not fail a test for non-proportional hazards (p = 0.213).
‡Did not fail a test for non-proportional hazards (p = 0.265).